Digital breast tomosynthesis(DBT) vs 2D mammography and impact of combined use: A meta-analysis

Authors

1) Dr. Dev Andharia, MBBS

Smt. NHL Municipal Medical College, Ahmedabad, India.

Email Address:- devu.andharia98@gmail.com

2) Dr. Hetvi Shah, MBBS

Smt. NHL Municipal Medical College, Ahmedabad, India.

Email Address:-shahhetvi1026@gmail.com

3) Dr. Anushka Dipakkumar Prajapati, MBBS

Smt. NHL Municipal Medical College, Ahmedabad, India.

Email: anushkap11@yahoo.com

4) Dr. Aayushi Darshan Bhansali, MBBS

Smt. NHL Municipal Medical College, Ahmedabad, India.

Email: abhansali2000@gmail.com

5) Dr. Abhijay B. Shah, MBBS

Smt. NHL Municipal Medical College, Ahmedabad, India.

Email Address:-abhijayshah0610@gmail.com

6) Dr. Dev Desai (Corresponding author), MBBS

Smt. NHL Municipal Medical College, Ahmedabad, India.

Email Address:-devhdesai01@gmail.com,

Mob No.:- +91 9173655551

Abstract

Background: Having breast cancer and receiving treatment for it is viewed as a very traumatic experience for women. From the recent advances in breast cancer diagnosis protocol; The triple assessment for a lump in the breast is the best practice and its application towards early disease detection is crucial. For which, 2D mammography is used. The limitation of this technique is a potential tissue overlap in dense breasts. Digital breast tomosynthesis (DBT) is a new imaging technology that can address the limitations of 2D mammography. This study aims to highlight the use of DBT.

Methods: The study population included all women aged from 18 to 80. For this analysis, the subdivision of the population is not created. A total of 28 RCTs with a total of 1,735,126 patients were selected for the DBT+FFDM vs FFDM study and 5 RCTs with a total of 554,419 patients were selected for the DBT vs FFDM study.

Results: For the DBT+FFDM vs FFDM; The overall diagnostic odds ratio was 1.28 with a 95%CI [1.22-1.33], the Decrease in RR is 2.43% and the increase in CDR is 1.583. for DBT vs FFDM; the overall diagnostic odds ratio was 1.38 with a 95%CI [1.28-1.50], a decrease in RR is 1.70%, and an increase in CDR is 1.4.

Conclusion: DBT+FFDM and DBT do outweigh FFDM alone.

Keywords: ‘3D vs 2D mammography’, ‘DBT+FFDM vs FFDM’, ‘DBT vs FFDM’, ‘Digital Breast Tomosynthesis-meta analysis’, ‘DBT vs DM’, ‘DBT vs 2d mammography’, and ‘3d and 2d mammography’.

Introduction:

Breast cancer is the most common cancer observed in females overall. Having breast cancer and receiving treatment for it is viewed as a very traumatic experience for women because this reflects on their self-image, sexual relationship, and self-confidence and this may lead to other psychological problems such as anxiety, denial, depression, anger, etc.[1] This is why early breast cancer detection with minimum recalls is useful to avoid fears and anxiety toward the disease.[2]

From the recent advances in breast cancer diagnosis protocol; The triple assessment for a lump in the breast is the best practice and its application towards early disease detection is crucial.[3] For screening of breast cancer, there are two main resources available; Mammography and a second clinical breast examination.[4]

For mammography, there are few options available, Conventional two-dimensional (2D) mammography is widely acknowledged as the most effective method for detecting breast cancer. A meta-analysis of 11 randomized trials concluded that mammography screening can lead to a reduction of 20% mortality in breast cancer.[5]

The limitation of this technique is a potential tissue overlap in dense breasts. This can consequently obscure the area of interest in the image, which can lead to false-negative and false-positive readings, following which recall of the patient for further imaging and biopsy will be needed. This explains 15-30% of undetected cancers by standard screening protocol. This can in turn be responsible for anxiety and non-attendance for the next routine breast screening tests.[6]

Digital breast tomosynthesis (DBT) is a new imaging technology that can address the limitation caused by overlapping structures in 2D mammography. This technique provides a dual benefit for screening purposes. First, DBT increases the cancer detection rate mostly by highlighting architectural distortions [AD] and allowing a better assessment of the shape and margins of the mass. Second, it helps reduce the recall rate. However, DBT is not included in the majority of cancer screening programs worldwide.[5], [7], [8]

The use of DBT with digital or synthetic mammography for breast cancer screenings increases the rates of overall and invasive breast cancer detection. however, no evidence shows that DBT, compared with digital or synthetic mammography may decrease recall rates, with high or moderate quality.[9]

This study aims to combine different results and create the most accurate meta-analysis to date to experience clinical routine use of tomosynthesis, with an evaluation of the added value of this technique by comparing the diagnostic accuracy with the increase in cancer detection rate [CDR] and decreases in recall rate [RR] of Digital breast tomosynthesis vs 2D mammography and DBT combined with 2D mammography vs the accuracy of 2D mammography alone.

From here onwards, Digital breast tomosynthesis [DBT] means 3D mammography and conventional mammography means 2D mammography; Full-Field Digital Mammography[FFDM]; Digital mammography[DM] or standard 2D mammography. These words are used interchangeably.

Image 1: PRISMA Flow chart



METHODOLOGY:

DATA COLLECTION

For the data collection, Researchers reviewed all relevant literature, a search was done using PubMed, Google Scholar, and Cochrane Library databases.

The used medical subject headings (MeSH) and keywords were the following: ‘3D vs 2D mammography’, ‘DBT+FFDM vs FFDM’, ‘DBT vs FFDM’, ‘Digital Breast Tomosynthesis-meta analysis’, ‘DBT vs DM’, ‘DBT vs 2d mammography’, and ‘3d and 2d mammography’.

For further data collection from all the articles, a review of all the references and meta-analyses available, titles and abstracts were read methodically, and papers with detailed information about the study group and control group were selected.

INCLUSION AND EXCLUSION CRITERIA

In this paper, the data is compiled for the studies that provided Recall rates and cancer detection rates in the women who were not exposed to the risk factors.

The main purpose of this study is to compare and provide the decrease in Recall rate and increase in cancer detection rate overall for the implementation of the DBT+FFDM method in routine screening protocol, The study population includes all women aged from 18 to up to 80. The subdivision of the population was not created as it is beyond the scope of this study. The following papers were excluded; Carbonaro et al 2016 [10], Michell et al 2012[11], and Chae et al 2016[12] as the study populations were exposed to risk factors thus hindering the result analysis.

Inclusion criteria were the following: 1) only articles in the English language were selected, 2) Articles providing DBT vs FFDM comparison. 3) Articles with DBT+FFDM vs FFDM comparison 4) articles providing either of the following cancer detection rate [CDR] and recall rate [RR].

Exclusion criteria were the following: 1) non-English language articles, 2) articles where the study group was exposed to the risk factors 3) articles where provisional diagnoses for the patient were given as architectural distortion. 4) articles not providing CDR or RR.

DATA EXTRACTION

According to PRISMA, a total of 28 RCTs with a total of 1,735,126 patients were selected for the DBT+FFDM vs FFDM study and 5 RCTs with a total of 554,419 patients were selected for the DBT vs FFDM study. Sumkin et al 2015 were only included in the RR table. Every appearing paper was independently studied by three different reviewers. Each article was analyzed for the number of patients, age, procedure modality, risk factors, BIRADs scoring of patients, recall rates, and cancer detection rate. Further discussion and consultation with the other authors and third-party reviewers were used to resolve conflicts. In the majority of the papers, the recall rate (RR) was calculated as the number of positive examinations (BI-RADS 0, 3, and 4) over the total number of screening examinations interpreted while Some papers considered only BI-RADS cat 0 for the calculation of RR. And some also include Cat 5. The modified Jadad score was employed to establish the quality of each paper for participation.

ASSESSMENT OF STUDY QUALITY

Three writers independently assessed the caliber of each included study. This test consists of 10 questions, each with a score between 0 and 2, with 20 being the maximum possible overall score. Two authors rated each article independently. For deciding the bias risk for RCTs, the Cochrane tool was applied. There were no assumptions made for any lacking or unclear material. There was no funding involved in collecting and reviewing the data analysis.

STATISTICAL ANALYSIS

For the determination of the odds ratio and other analyses, The statistical software packages RevMan (Review Manager, version 5.3), SPSS (Statistical Package for the Social Sciences, version 20), and Excel were used. Fixed- and random-effects models were used to estimate diagnostic odds ratios (DOR) with 95 percent confidence intervals to examine critical clinical outcomes. The odds ratio of the individual study was plotted on the funnel plot and forest chart.

BIAS STUDY

The risk of bias was evaluated by the QUADAS-2 analysis. which includes 4 Major parameters, as follows; 1. Patient selection, 2. Index test, 3. Reference standard, 4. The patient flow and Timing of the Index tests.

RESULT:

Table 1: Table of the description of papers

Author Name and Year	Location	Duration of the study	Population	Study design	Modalities	Increase in CDR		Decrease in Recall rate	
						DBT	DBT+DM	DBT	DBT+DM

						v DM	v DM	v DM	v DM
Alsheik et al 2019[13]	US	Jun 2015-Sept 2017	99660 (DM) 95370 (DBT)	Prospective study	DBT vs DM	1		-2.15	
Aujero et al 2017[14]	US	Oct 2011-Jun 2016	32076 (DM) 30561 (DBT +DM)	Retrospective study	DBT+DM vs DM		1.1		-2.9
Bahl et al 2018[15]	US	Jan 2009-Feb 2011 (DM) Jan 2013-Feb 2015 (DBT)	78 385 (DM) 76 896 (DBT +DM)	Retrospective study	DBT+DM vs DM		ResultA: 0 ResultB: 0		
Bernardi et al 2016[16]	Italy	May 2013-May 2015	9677 (DM) 9677 (DBT +DM)	Prospective study	DBT+DM vs DM		2.2		0.55
Chikarmane et al 2020[17]	US	Oct 2014-Sept 2016 (DM) Feb 2017-Dec 2018 (DBT)	5706 (DM) 4440 (DBT +DM)	Retrospective study	DBT+DM vs DM		0.1		-2.24
Ciatto et al 2013[18]	Italy	Aug 2011-Jun 2012	7294 (DM) 7294 (DBT +DM)	Prospective comparison study	DBT+DM vs DM		2.8		-1
Cohen et al 2018[19]	US	Feb 2011-Jun 2014	71656 (DM) 31414 (DBT +DM)	Retrospective review	DBT+DM vs DM		0.8		-1.8
Conant et al 2016[20]	US	Jan 2011-Dec 2014	113061 (DM) 25268 (DBT +DM)	Retrospective analysis of prospective data	DBT+DM vs DM		1.5		-1.7
Conant et al 2020[21]	US	Sept 2010-Sept 2016	10511 (DM) 56839 (DBT)	Retrospective study	DBT vs DM	1		-2.4	
Destounis et al 2014[22]	US	Jun 2011-Dec 2011	524 (DM) 524 (DBT +DM)	Retrospective review	DBT+DM vs DM		1.9		-7.25
Durand et al 2015[23]	US	Aug 2011-Dec 2012	9364 (DM) 8591 (DBT +DM)	Retrospective review	DBT+DM vs DM		0.2		-4.5
Friedewald et al 2014[24]	US	Mar 2010-Dec 2012	2,80,698 (DM) 1,72,727 (DBT +DM)	Retrospective multi-centre analysis	DBT+DM vs DM		1.2		-1.63
Giess et al 2017[25]	US	Oct 2012-May 2015	14180 (DM) 9817 (DBT +DM)	Retrospective study	DBT +DM vs DM		2		0.4
Greenberg et al 2014[26]	US	Aug 2011-Nov 2012	38674 (DM) 20943 (DBT +DM)	Retrospective multisite study	DBT+DM vs DM		1.4		-2.6
Haas et al 2013[27]	US	Oct 2011-Sept 2012	7058 (DM) 6100 (DBT +DM)	Retrospective study	DBT+DM vs DM		0.5		-3.6

Heindel et al 2022[28]	Germany	July 2018-Dec 2020	49762 (DM) 49 715 (DBT +DM)	Prospective RCT	DBT+DM vs DM		2.3		
Houssami et al 2014[29]	Italy	Aug 2011-Jun 2012	7292 (DM) 7292 (DBT +DM)	Prospective study	DBT+DM vs DM		ResultA: 2.7 ResultB: 2.8		ResultA: -0.9 ResultB: -1
Houssami et al 2017[30]	Italy	May 2013-May 2015	9677 (DM) 9677 (DBT +DM)	Secondary analysis Prospective study	DBT+DM vs DM		1.9		
Lang et al 2016[31]	Sweden	Jan 2010-Dec 2012	7500 (DM) 7500 (DBT +DM)	Prospective study	DBT +DM vs DM		2.6		1.2
Lourenco et al 2015[32]	US	Mar 2011-Feb 2012 (DM) Mar 2012-Feb 2013 (DBT)	12577 (DM) 12921 (DBT)	Retrospective study	DBT vs DM	0.4		-2.94	
McCarthy et al 2014[33]	US	Sept 2010-Aug 2011 (DM) Oct 2011-Feb 2013 (DBT +DM)	10728 (DM) 15571 (DBT +DM)	Retrospective – Prospective study	DBT +DM vs DM		0.9		-1.6
McDonald et al 2015[34]	US	Sept 2010-Aug 2011 (DM) Oct 2011-Feb 2013 (DBT +DM)	10728 (DM) 15571 (DBT +DM)	Retrospective study	DBT +DM vs DM		ResultA: 1.7 ResultB: 0.8		ResultA: -4.5 ResultB: -1.3
McDonald et al 2016[35]	US	Sept 2010-Sept 2014	10728 (DM) 33740 (DBT +DM)	Retrospective study	DBT +DM vs DM		ResultA: 1.5 ResultB: 1.2 ResultC: 0.9		ResultA: -1.6 ResultB: -1.4 ResultC: -1.2
Pattacini et al 2018[36]	Italy	Mar 2015-Mar 2016	9783 (DM) 9777 (DBT +DM)	Prospective RCT	DBT+DM vs DM		4.1		0
Powell et al 2017[37]	US	Jun 2012-Aug 2014	10477 (DM) 2304 (DBT +DM)	Retrospective study	DBT +DM vs DM		2.6		-2.33
Rose et al 2013[38]	US	May 2011-Jan 2012	13856 (DM) 9499 (DBT +DM)	Retrospective study	DBT+DM vs DM		1.33		-3.2
Rose et al 2014[39]	US	May 2011-Jan 2012	10878 (DM) 10878 (DBT +DM)	Prospective interpretations of DBT compared with Retrospective readings of DM	DBT+DM vs DM		1.9		-2.8
Roth et al 2014[40]	US	Sept 2010-	10751 (DM)	Interval analysis	DBT+DM vs DM		1		-1.6

		Aug 2011 (DM) Sept 2011-Aug 2012 (DBT+DM)	11115 (DBT +DM)						
Sharpe et al 2016[41]	US	Jan 2011-Mar 2014	80149 (DM) 5703 (DBT +DM)	Prospective study with Retrospective cohort	DBT +DM vs DM		1.9		-1.41
Skaane et al 2013[42]	Norway	Nov 2010-Dec 2011	12621 (DM) 12621 (DBT +DM)	Prospective study	DBT+DM vs DM		2.3		-0.77
Starikov et al 2016[43]	US	Jan 2013-Dec 2013	12157 (DM) 2070 (DBT +DM)	Retrospective cohort	DBT+DM vs DM		2.1		-7.3
Sumkin et al 2015 [44]	US	May 2010-Sept 2014	1074 (DM) 1074 (DBT +DM)	Prospective single-site clinical study	DBT+ DM vs DM				-12.9
Winter et al 2020[45]	US	Jan 2012-Dec 2014 (DM) Jan 2016-Dec 2018 (DBT)	117099 (DM) 119746 (DBT)	Retrospective study	DBT vs DM	2.4		-2.1	
Zackrisson et al 2018[46]	Sweden	Jan 2010-Feb 2015	14848 (DM) 14848 (DBT)	Prospective survey	DBT vs DM	2.2		1.1	

Study or Subgroup	DBT+FFDM Events	DBT+FFDM Total	FFDM Events	FFDM Total	Weight	Odds Ratio M-H, Fixed, 95% CI
Aujero et al 2017	194	30561	169	32076	5.0%	1.21 [0.98, 1.48]
behl et al. 2018	84	76986	83	78835	2.5%	1.04 [0.77, 1.40]
Behl et al. 2018	387	76986	394	78835	11.8%	1.01 [0.87, 1.16]
Bernardi et al. 2016	82	9677	61	9677	1.8%	1.35 [0.97, 1.88]
Chikarmane et al, 2020	27	4440	35	5706	0.9%	0.99 [0.60, 1.64]
Ciatto et al. 2013	59	7294	39	7294	1.2%	1.52 [1.01, 2.28]
Cohen et al 2018	151	31414	287	71656	5.3%	1.20 [0.99, 1.46]
Conant et al. 2016	149	25268	499	113061	5.5%	1.34 [1.11, 1.61]
Destounis et al. 2014	3	524	2	524	0.1%	1.50 [0.25, 9.03]
Durand et al.2015	51	8591	54	9364	1.6%	1.03 [0.70, 1.51]
Friedewald et al. 2014	950	172727	1207	280698	27.8%	1.28 [1.18, 1.39]
Giess et al 2017	37	9817	26	14180	0.6%	2.06 [1.25, 3.40]
Greenberg et al. 2014	131	20943	190	38674	4.0%	1.27 [1.02, 1.59]
Haas et al. 2013	35	6100	37	7058	1.0%	1.10 [0.69, 1.74]
Heindel et al, 2022	354	49715	240	49762	7.2%	1.48 [1.26, 1.74]
houssami et al 2014	55	7292	35	7292	1.1%	1.58 [1.03, 2.41]
Houssami et al 2014	59	7292	39	7292	1.2%	1.52 [1.01, 2.28]
Houssami et al 2017	79	9677	61	9677	1.8%	1.30 [0.93, 1.81]
Lang et al. 2016	67	7500	47	7500	1.4%	1.43 [0.98, 2.08]
McCarthy et al 2014	85	15571	49	10728	1.8%	1.20 [0.84, 1.70]
McDonald 2015	11	1859	5	1204	0.2%	1.43 [0.49, 4.12]
McDonald 2016	61	11007	49	10728	1.5%	1.21 [0.83, 1.77]
McDonald et al 2015	74	13712	44	9524	1.6%	1.17 [0.80, 1.70]
McDonald et al 2016	65	11157	49	10728	1.5%	1.28 [0.88, 1.85]
MCDonald et al 2016	71	11576	49	10728	1.5%	1.34 [0.93, 1.94]
Pattacini et al 2018	83	9777	44	9783	1.3%	1.90 [1.31, 2.73]
Powell et al. 2017	18	2304	54	10477	0.6%	1.52 [0.89, 2.60]
Rose et al 2013	51	9499	56	13856	1.4%	1.33 [0.91, 1.95]
Rose et al 2014	59	10878	38	10878	1.1%	1.56 [1.03, 2.34]
Roth et al 2014	60	11115	47	10751	1.4%	1.24 [0.84, 1.81]
Sharpe et al 2016	31	5703	280	80149	1.1%	1.56 [1.07, 2.26]
Skaane et al 2013	119	12621	90	12621	2.7%	1.33 [1.01, 1.74]
Starikov et al 2016	11	2070	39	12157	0.3%	1.66 [0.85, 3.25]
Total (95% CI)		**691653**		**1043473**	**100.0%**	**1.28 [1.22, 1.33]**
Total events	3753		4398			

Heterogeneity: Chi² = 33.91, df = 32 (P = 0.38); I² = 6%

Test for overall effect: Z = 10.56 (P < 0.00001)



Image 2: Forest chart of DBT+FFDM vs FFDM



Image 3: Funnel plot of DBT+FFDM vs FFDM

DBT+FFDM vs FFDM

A total of 28 RCTs with 1,735,126 patients were selected for the study of DBT+FFDM vs FFDM arm. In Image 2, the forest chart and in Image 3, funnel plots are described. This image suggests as the sample size increases, the odds ratio increases, which can be seen in Cohen et al 2019, Conant et al 2016, Friedewald et al 2014, Greenberg et al 2014, and Heindel et al 2022. The overall diagnostic odds ratio was 1.28 with a 95%CI [1.22 to 1.33].



Study or Subgroup	DBT Events	DBT Total	FFDM Events	FFDM Total	Weight	Odds Ratio M-H, Fixed, 95% CI
Alsheik et al 2019	497	95370	429	99660	37.9%	1.21 [1.06, 1.38]
Conant et al. 2020	341	56839	53	10511	8.1%	1.19 [0.89, 1.59]
Lourenco et al 2015	93	12921	86	12577	7.9%	1.05 [0.78, 1.41]
winterv et al. 2020	709	119746	411	117099	37.5%	1.69 [1.50, 1.91]
Zackrisson et al 2018	129	14848	97	14848	8.7%	1.33 [1.02, 1.74]
Total (95% CI)		**299724**		**254695**	**100.0%**	**1.39 [1.28, 1.50]**
Total events	1769		1076			

Heterogeneity: Chi² = 18.87, df = 4 (P = 0.0008); I² = 79%
Test for overall effect: Z = 8.26 (P < 0.00001)

Image 4: Forest chart of DBT vs FFDM



Image 5: Funnel plot of DBT vs FFDM

DBT vs FFDM

A total of 5 RCTS with 554,419 patients were selected for this study, image 4 describes the forest charts and image 5 describes the funnel plot. Here overall diagnostic odds ratio was 1.38 with a 95%CI [1.28 to 1.50]. here, it is also notable that an increase in sample size leads to an increase in the odds ratio for DBT. This can be seen in Alsheik et al 2019 and Winter et al 2020.

Table 2: Decrease in recall for DBT+FFDM vs FFDM

	intervention	intervention		Control	Control		
	DBT + DM	DBT + DM		DM	DM		
	Event (recalled people)	Total	recall rate	Event (recalled people)	Total	recall rate	Difference
Chikarmane et al, 2020	349	4440	7.86%	575	5706	10.10%	-2.24%
Bernardi et al. 2016	381	9587	3.97%	328	9587	3.42%	0.55%
Ciatto et al. 2013	73	72 35	1%	141	72 35	2%	-1%
Skaane et al 2013	365	12,621	2.89%	463	12,621	3.66%	-0.77%
haas et al. 2013	512	6100	8.40%	847	7058	12.00%	-3.60%
Durand et	671	8591	7.80%	1154	9364	12.30%	-4.50%

al.2015							
Conant et al. 2016	4856	55,998	8.70%	14884	142,883	10.40%	-1.70%
Destounis et al. 2014	22	524	4.20%	60	524	11.45%	-7.25%
Greenberg et al. 2014	2845	20,943	13.60%	6247	38,674	16.20%	-2.60%
Friedewald et al. 2014	15541	173663	8.94%	29726	281187	10.57%	-1.63%
Rose et al. 2013	518	9499	5.50%	1208	13,856	8.70%	-3.20%
Aujero et al 2017	1785	30,561	5.80%	2799	32,076	8.70%	-2.90%
Cohen et al 2018	1914	31,414	6.10%	5641	71,656	7.90%	-1.80%
Pattacini et al 2018	344	9777	3.50%	339	9783	3.50%	0.00%
Rose et al 2014	588	10,878	5.40%	888	10,878	8.20%	-2.80%
Roth et al 2014	978	11,115	8.80%	1118	10,751	10.40%	-1.60%
Sumkin et al 2015	274	1074	25.50%	412	1074	38.40%	-12.90%
Starikov et al 2016	211	2070	10.20%	2128	12,157	17.50%	-7.30%
Houssami et al 2014	56	7292	0.80%	124	7292	1.70%	-0.90%
Houssami et al 2014	73	7292	1.00%	141	7292	2.00%	-1.00%
Lång et al. 2016	282	7500	3.80%	197	7500	2.60%	1.20%
Powell et al. 2017	319	2,304	13.84%	1,694	10,477	16.17%	-2.33%
Sharpe et al 2016	341	5587	6.10%	5270	70173	7.51%	-1.41%
McCarthy et al 2014	1366	15571	8.80%	1112	10728	10.40%	-1.60%
Giess et al 2017	2254	21,074	10.70%	1683	16,264	10.30%	0.40%
McDonald et al 2015	298	1859	16%	247	1204	20.50%	-5%
McDonald et al 2015	1068	13,712	7.80%	865	9524	9.10%	-1.30%
McDonald et al 2016	969	11,007	8.80%	1116	10728	10.40%	-1.60%
McDonald et al 2016	1004	11157	9.00%	1116	10728	10.40%	-1.40%
McDonald et al 2016	1065	11576	9.20%	1116	10728	10.40%	-1.20%
Average			7.80%			10.46%	-2.43%
P < 0.0001							

Table 3: Decrease in Recall Rate for DBT vs FFDM

	intervention	intervention		Control	Control		
	DBT	DBT		dm	dm		
	Event (recalled people)	Total	Recall rate	Event (recalled people)	Total	recall rate	Difference
winter et al. 2020	10347	119746	8.60%	12508	117099	10.70%	-2.10%
Lourenco et al 2015	827	12921	6.40%	1175	12577	9.34%	-2.94%
Alsheik et al 2019	17,165	194,437	8.83%	14,415	131,292	10.98%	-2.15%
Conant et al. 2020	4547	56839	8.00%	1093	10511	10.40%	-2.40%
Zackrisson et al 2018	535	14848	3.60%	371	14848	2.50%	1.10%
Average			7.09%			8.78%	-1.70%
P < 0.0001							

Decrease in the recall rate

Patients within the screening with BI-RADS 0, 3, 4, or 5 were recalled for further investigation and the recall rate was calculated.

Table 2 and Table 3 show a decrease in recall rate for DBT+FFDM and DBT respectively. For DBT+FFDM vs FFDM, the decrease in recall rate is 2.43% overall. For DBT vs FFDM, the average decrease in recall rate was 1.70%.

Table 4: Cancer detection rate for DBT+FFDM vs FFDM

CDR/1000	DBT + DM	DM	Difference
Heindel et al, 2022	7.1	4.8	2.3
Chikarmane et al, 2020	6.1	6	0.1

Table 5: Cancer detection rate for DBT vs FFDM

	DBT	DM	Difference
Friedewald et al. 2014	5.9	3.5	2.4
Rose et al. 2013	6	5	1
Zackrisson et al 2018	8.7	6.5	2.2
Alsheik et al 2019	4.8	3.8	1
Lourenco et al 2015	7.2	6.8	0.4

bahl et al. 2018	1.1	1.1	0
bahl et al. 2018	5	5	0
Bernardi et al. 2016	8.5	6.3	2.2
Ciatto et al. 2013	8.1	5.3	2.8
Skaane et al 2013	9.4	7.1	2.3
haas et al. 2013	5.7	5.2	0.5
Durand et al.2015	5.9	5.7	0.2
Conant et al. 2016	5.9	4.4	1.5
Destounis et al. 2014	5.7	3.8	1.9
Greenberg et al. 2014	6.3	4.9	1.4
CDR1000	5.5	4.3	1.2
Winter et al. 2020	5.37	4.04	1.33
Conant et al. 2020	6.4	5.3	1.1
Houssami et al 2017	8.2	6.3	1.9
Cohen et al 2018	4.8	4	0.8
Pattacini et al 2018	8.6	4.5	4.1
Rose et al 2014	5.4	3.5	1.9
Roth et al 2014	5.4	4.4	1
Starikov et al 2016	5.3	3.2	2.1
Houssami et al 2014	7.5	4.8	2.7
Houssami et al 2014	8.1	5.3	2.8
Lång et al. 2016	8.9	6.3	2.6
Powell et al. 2017	7.8	5.2	2.6
Sharpe et al 2016	5.4	3.5	1.9
McCarthy et al 2014	5.5	4.6	0.9
Giess et al 2017	3.8	1.8	2
McDonald et al 2015	5.9	4.2	1.7
McDonald et al 2015	5.4	4.6	0.8
McDonald et al 2016	5.5	4.6	0.9
McDonald et al 2016	5.8	4.6	1.2
McDonald et al 2016	6.1	4.6	1.5
Average	6.226	4.643	1.582
P < 0.0001			

Average	6.52	5.12	1.4
P = 0.1776			

Increase in Cancer detection rate

Table 4 and Table 5 show an increase in cancer detection rate for DBT+FFDM and DBT respectively. The average increase in cancer detection rate was 1.583 for DBT+FFDM and for DBT it was 1.4.

Bias Study:

Table 6: Risk of bias and applicability concern

	Author Name and Year	Patient Selection	Index test	Reference standard	Flow and timing		Patient selection	Index test	Reference standard
1	Alsheik et al 2019	low	low	High	high		high	low	low
2	Aujero et al 2017	Low	low	Low	low		Low	Low	low
3	Bahl et al 2018	low	low	low	high		low	low	low
4	Bernardi et al 2016	unclear	low	Low	high		low	low	low
5	Chikarmane et al 2020	low	low	low	unclear		unclear	low	low
6	Ciatto et al 2013	Low	Unclear	Low	Low		low	low	Low
7	Cohen et al 2018	Low	Low	Unclear	Low		Low	Low	Low
8	Conant et al 2016	Low	Unclear	Low	Low		Low	unclear	Low
9	Conant et al 2020	Low	Low	Low	unclear		Unclear	Low	low
10	Destounis et al 2014	Low	High	unclear	Low		Low	Low	unclear
11	Durand et al 2015	unclear	Low	Low	unclear		Low	Low	low
12	Friedewald et al 2014	Low	Unclear	Low	Low		Low	unclear	low
13	Giess et al 2017	low	Low	High	high		high	low	low
14	Greenberg et al 2014	low	Low	unclear	unclear		low	low	low

15	Haas et al 2013	Low	Low	Low	Low		Unclear	Low	unclear
16	Heindel et al 2022	Low	Low	Low	low		Low	Unclear	low
17	Houssami et al 2014	Low	Low	Low	Low		Unclear	Low	unclear
18	Houssami et al 2017	unclear	Low	unclear	low		Low	Low	low
19	Lang et al 2016	Low	low	Low	unclear		Low	Low	unclear
20	Lourenco et al 2015	Low	Unclear	Low	Low		low	high	Low
21	McCarthy et al 2014	Low	unclear	high	Low		Low	Low	unclear
22	McDonald et al 2015	Low	High	Low	unclear		Low	Low	low
23	McDonald et al 2016	Low	Low	Low	Low		Unclear	Low	unclear
24	Pattacini et al 2018	unclear	low	Low	Low		Low	high	unclear
25	Powell et al 2017	low	Low	unclear	high		Low	Low	low
26	Rose et al 2013	Low	Unclear	Low	Low		low	low	Low
27	Rose et al 2014	Low	Unclear	Low	Low		low	low	Low
28	Roth et al 2014	unclear	low	Low	low		Low	Low	low
29	Sharpe et al 2016	Low	low	high	Low		Low	Low	low
30	Skaane et al 2013	Low	low	Low	low		Low	unclear	low
31	Starikov et al 2016	Low	low	unclear	low		Low	Low	low

32	Sumkin et al 2015	low	low	high	low		high	low	low
33	Winter et al 2020	low	low	low	high		low	unclear	low
34	Zackrisson et al 2018	low	low	low	low		low	unclear	low



Image 6: Risk of Bias and Applicability Concern

Publication Bias:

The summary of publication bias for DBT+FFDM vs FFDM and DBT vs FFDM is shown in (image 6). For the publication bias, In, patient selection, bias was low for 29 studies and unclear for 5. In the index test, bias was low in 25 studies, unclear in 7, and high in 2 studies. While for the reference standard, the bias was low in 23, unclear in 6, and high in 5 studies. The flow and timing bias was low in 22, unclear in 6, and high in 6. The applicability concerns bias in patient selection were low in 26, unclear in 5, and high in 3 studies. The index test bias was low in 26, unclear in 6, and high in 2. The reference standard bias was low in 27, and unclear in 7.

Discussion:

To present the best available evidence to help clinicians with decision-making, this study was conducted as a meta-analysis. The primary aim of this study was to evaluate the increase in cancer detection rate[CDR] and decrease in recall rate[RR] for 3D+2D vs 2D and 3D vs 2D mammography. The cancer detection rate was calculated per 1000 population screened, and every patient with BI-RADS category for highly suggestive cat 5 and cat 6. The results show, with a mild to moderate quality of evidence, that implementing DBT plus digital or synthetic mammography in population-based breast cancer screening increases overall breast cancer detection rates, and decreases recall rate.

For Lourenco et al 2015, the screening examinations performed during this study are taken as the total population and not the actual population as the data is provided in such a way in the paper.

Multiple studies have shown that DBT can substitute mammographic spot compression views for the evaluation of noncalcified lesions. The decrease in RR for asymmetries and focal asymmetries with DBT is related to improved characterization of overlapping breast tissue as a benign finding, which would reduce RR for summation of overlapping tissue. It may also be related to improved visualization of mass margins. According to Zuley et al 2013, By using tomosynthesis in the screening, radiologists were able to find fewer benign masses as BIRADS category 3, 4, or 5, without loss of much sensitivity, and malignant lesions were found as highly suggestive of malignancy (BI-RADS category 5), and with the help of tomosynthesis, radiologists were able to differentiate between malignant and benign lesions better. [47]–[50]

In this study, The CDR is identified with an average of 1.28 for 3D+2D vs 2D and 1.39 for 3D vs 2D study design. It has been seen in the result that the incorporation of DBT into conventional 2D mammography does increase the CDR. However, in comparison to radiation exposure, 3D+2D is almost double the exposure than 2D alone. This may theoretically limit the application of DBT with DM.[5]

As the usage of DBT in screening is limited, it may be very useful for the detection of benign Architectural distortions and Assessment of symptomatic women and work-up of screening-detected suspicious findings as lumps are identified by their shape, size margins, density, and content. The shape of a lesion is often better defined at DBT and DBT+FFDM than FFDM alone.[50], [51]

However, DBT-guided FNAC, DBT-guided vacuum-assisted breast biopsy, Contrast-media-enhanced DBT, and Fusion imaging like DBT with other 3D modalities such as 3D-automated breast ultrasound, radionuclide imaging, or even MRI is a promising research approach.[5], [52]

With some of these limitations of the radiation exposure from DBT, there is a new opportunity for using 2D synthesised-3D mammography, which may show less radiation exposure and almost the same or more CDR than DBT+FFDM.

Limitations:

This study has not divided the study population into sub-age groups and also some papers only involved BIRADS cat 0 in RR. For the diagnosis and incorporation into

the routine screening, DBT requires more time and study and the equipment is costlier.

Conclusion:

As shown above, DBT+FFDM and DBT do outweigh FFDM alone and must be used with precaution and proper understanding of reading it as it can identify more cancers and can separate benign from malignancy better for BI-RADS 1,2 and highly suggestive of malignancy cat 5 and cat 6. In clinical practice, the use of

tomosynthesis is likely to provide a lower recall rate, an increase in cancer detection rate, fewer screening examinations, fewer short-interval follow-up studies, and fewer biopsies for patients with benign lesions. Thus, relieving anxiety and resources of the patients and hospitals. Using this technology, patients can benefit more than its side effects. For hospitals where the patient load is very high and facilities that provide mass population screening and community diagnosis, these modalities can be implemented for the betterment of the population.

References:

[1] K. Tsaras *et al.*, "Assessment of Depression and Anxiety in Breast Cancer Patients: Prevalence and Associated Factors," *Asian Pacific Journal of Cancer Prevention*, vol. 19, no. 6, pp. 1661–1669, 2018, doi: 10.22034/APJCP.2018.19.6.1661.

[2] J. A. Merino Bonilla, M. Torres Tabanera, and L. H. Ros Mendoza, "El cáncer de mama en el siglo XXI: de la detección precoz a los nuevos tratamientos," *Radiologia*, vol. 59, no. 5, pp. 368–379, Sep. 2017, doi: 10.1016/j.rx.2017.06.003.

[3] M. O. Karim, K. A. Khan, A. J. Khan, A. Javed, S. Fazid, and M. I. Aslam, "Triple Assessment of Breast Lump: Should We Perform Core Biopsy for Every Patient?," *Cureus*, Mar. 2020, doi: 10.7759/cureus.7479.

[4] J. G. Elmore, M. B. Barton, V. M. Moceri, S. Polk, P. J. Arena, and S. W. Fletcher, "Ten-Year Risk of False Positive Screening Mammograms and Clinical Breast Examinations," *New England Journal of Medicine*, vol. 338, no. 16, pp. 1089–1096, Apr. 1998, doi: 10.1056/NEJM199804163381601.

[5] C. Mandoul *et al.*, "Breast tomosynthesis: What do we know and where do we stand?," *Diagn Interv Imaging*, vol. 100, no. 10, pp. 537–551, Oct. 2019, doi: 10.1016/j.diii.2019.07.012.

[6] M. G. Marmot, D. G. Altman, D. A. Cameron, J. A. Dewar, S. G. Thompson, and M. Wilcox, "The benefits and harms of breast cancer screening: an independent review," *Br J Cancer*, vol. 108, no. 11, pp. 2205–2240, Jun. 2013, doi: 10.1038/bjc.2013.177.

[7] N. Tirada *et al.*, "Digital Breast Tomosynthesis: Physics, Artifacts, and Quality Control Considerations," *RadioGraphics*, vol. 39, no. 2, pp. 413–426, Mar. 2019, doi: 10.1148/rg.2019180046.

[8] D. Bernardi *et al.*, "Application of breast tomosynthesis in screening: incremental effect on mammography acquisition and reading time," *Br J Radiol*, vol. 85, no. 1020, pp. e1174–e1178, Dec. 2012, doi: 10.1259/bjr/19385909.

[9] R. R. Giampietro, M. V. G. Cabral, S. A. M. Lima, S. A. T. Weber, and V. dos Santos Nunes-Nogueira, "Accuracy and Effectiveness of Mammography versus Mammography and Tomosynthesis for Population-Based Breast Cancer Screening: A Systematic Review and Meta-Analysis," *Sci Rep*, vol. 10, no. 1, p. 7991, May 2020, doi: 10.1038/s41598-020-64802-x.

[10] L. A. Carbonaro *et al.*, "Impact on the recall rate of digital breast tomosynthesis as an adjunct to digital mammography in the screening setting. A double reading experience and review of the literature," *Eur J Radiol*, vol. 85, no. 4, pp. 808–814, Apr. 2016, doi: 10.1016/j.ejrad.2016.01.004.

[11] M. J. Michella *et al.*, "A comparison of the accuracy of film-screen mammography, full-field digital mammography, and digital breast tomosynthesis".

[12] E. Y. Chae, H. H. Kim, J. H. Cha, H. J. Shin, and W. J. Choi, "Detection and characterization of breast lesions in a selective diagnostic population: diagnostic accuracy study for comparison between one-view digital breast tomosynthesis and two-view full-field digital mammography".

[13] N. H. Alsheik *et al.*, “Comparison of Resource Utilization and Clinical Outcomes Following Screening with Digital Breast Tomosynthesis Versus Digital Mammography: Findings From a Learning Health System”.

[14] M. P. Aujero, S. C. Gavenonis, R. Benjamin, Z. Zhang, and J. S. Holt, “Clinical Performance of Synthesized Two-dimensional Mammography Combined with Tomosynthesis in a Large Screening Population”.

[15] M. Bahl, S. Gaffney, A. M. McCarthy, K. P. Lowry, P. A. Dang, and C. D. Lehman, “Breast Cancer Characteristics Associated with 2D Digital Mammography versus Digital Breast Tomosynthesis for Screening-detected and Interval Cancers”.

[16] D. Bernardi *et al.*, “Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study”.

[17] S. A. Chikarmane, L. R. Cochon, R. Khorasani, S. Sahu, and C. S. Giess, “Screening Mammography Performance Metrics of 2D Digital Mammography Versus Digital Breast Tomosynthesis in Women With a Personal History of Breast Cancer”.

[18] S. Ciatto *et al.*, “Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study”.

[19] E. O. Cohen, H. H. Tso, K. A. Phalak, R. C. Mayo, and J. W. T. Leung, “Screening Mammography Findings From One Standard Projection Only in the Era of Full-Field Digital Mammography and Digital Breast Tomosynthesis”.

[20] E. F. Conant *et al.*, “Breast cancer screening using tomosynthesis in combination with digital mammography compared to digital mammography alone: a cohort study within the PROSPR consortium”.

[21] E. F. Conant *et al.*, “Five Consecutive Years of Screening with Digital Breast Tomosynthesis: Outcomes by Screening Year and Round”.

[22] S. Destounis, A. Arieno, and R. Morgan, “Initial experience with combination digital breast tomosynthesis plus full field digital mammography or full field digital mammography alone in the screening environment”.

[23] M. A. Durand *et al.*, “Early clinical experience with digital breast tomosynthesis for screening mammography”.

[24] S. M. Friedewald *et al.*, “Breast cancer screening using tomosynthesis in combination with digital mammography”.

[25] C. S. Giess, S. Pourjabbar, I. K. Ip, R. Lacson, E. Alper, and R. Khorasani, “Comparing Diagnostic Performance of Digital Breast Tomosynthesis and Full-Field Digital Mammography in a Hybrid Screening Environment”.

[26] J. S. Greenberg, M. C. Javitt, J. Katzen, S. Michael, and A. E. Holland, “Clinical performance metrics of 3D digital breast tomosynthesis compared with 2D digital mammography for breast cancer screening in community practice”.

[27] B. M. Haas, V. Kalra, J. Geisel, M. Raghu, M. Durand, and L. E. Philpotts, “Comparison of tomosynthesis plus digital mammography and digital mammography alone for breast cancer screening”.

[28] W. Heindel *et al.*, “Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial”.

[29] N. Houssami *et al.*, “Breast screening using 2D-mammography or integrating digital breast tomosynthesis (3D-mammography) for single-reading or double-reading–evidence to guide future screening strategies”.

[30] N. Houssami *et al.*, “Breast cancer detection using single-reading of breast tomosynthesis (3D-mammography) compared to double-reading of 2D-mammography: Evidence from a population-based trial”.

[31] K. Lång, I. Andersson, A. Rosso, P. Timberg, and S. Zackrisson, “Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the Malmö Breast Tomosynthesis Screening Trial, a population-based study”, doi: 10.1007/s00330-015-3803-3.

[32] A. P. Lourenco, M. Barry-Brooks, G. L. Baird, A. Tuttle, and M. B. Mainiero, “Changes in recall type and patient treatment following implementation of screening digital breast tomosynthesis”.

[33] A. M. McCarthy *et al.*, “Screening outcomes following implementation of digital breast tomosynthesis in a general-population screening program”.

[34] E. S. McDonald, A. M. McCarthy, A. L. Akhtar, M. B. Synnestvedt, M. Schnall, and E. F. Conant, “Baseline Screening Mammography: Performance of Full-Field Digital Mammography Versus Digital Breast Tomosynthesis,” *American Journal of Roentgenology*, vol. 205, no. 5, pp. 1143–1148, Nov. 2015, doi: 10.2214/AJR.15.14406.

[35] M. D. E. S. McDonald, M. A. Oustimov, S. P. Weinstein, M. B. Synnestvedt, P. M. S. MD, and M. E. F. Conant, “Effectiveness of Digital Breast Tomosynthesis Compared With Digital Mammography Outcomes Analysis From 3 Years of Breast Cancer Screening”.

[36] P. Pattacini *et al.*, “Digital Mammography versus Digital Mammography Plus Tomosynthesis for Breast Cancer Screening: The Reggio Emilia Tomosynthesis Randomized Trial”.

[37] J. L. Powell *et al.*, “Impact of the Addition of Digital Breast Tomosynthesis (DBT) to Standard 2D Digital Screening Mammography on the Rates of Patient Recall, Cancer Detection, and Recommendations for Short-term Follow-up”.

[38] S. L. Rose, A. L. Tidwell, L. J. Bujnoch, A. C. Kushwaha, A. S. Nordmann, and R. S. Jr, “Implementation of breast tomosynthesis in a routine screening practice: an observational study”.

[39] S. L. Rose, A. L. Tidwell, M. F. Ice, A. S. Nordmann, R. Sexton, and D. O. R. Song, “A Reader Study Comparing Prospective Tomosynthesis Interpretations with Retrospective Readings of the Corresponding FFDM Examinations”.

[40] R. G. Roth, A. D. A. Maidment, S. P. Weinstein, S. O. Roth, and E. F. Conant, “Digital Breast Tomosynthesis: Lessons Learned from Early Clinical Implementation”.

[41] R. E. S. Jr *et al.*, “Increased Cancer Detection Rate and Variations in the Recall Rate Resulting from Implementation of 3D Digital Breast Tomosynthesis into a Population-based Screening Program”.

[42] P. Skaane *et al.*, “Prospective trial comparing full-field digital mammography (FFDM) versus combined FFDM and tomosynthesis in a population-based screening programme using independent double reading with arbitration,” *Eur Radiol*, vol. 23, no. 8, pp. 2061–2071, Aug. 2013, doi: 10.1007/s00330-013-2820-3.

[43] A. Starikov, M. Drotman, K. Hentel, J. Katzen, R. J. Min, and E. K. Arleo, “2D mammography, digital breast tomosynthesis, and ultrasound: which should be used for the different breast densities in breast cancer screening?”.

[44] J. H. Sumkin *et al.*, “Recall Rate Reduction with Tomosynthesis During Baseline Screening Examinations,” *Acad Radiol*, vol. 22, no. 12, pp. 1477–1482, Dec. 2015, doi: 10.1016/j.acra.2015.08.015.

[45] A. M. Winter, S. Kazmi, A. K. Hardy, and D. L. Bennett, “Comparison of interval breast cancers with 2D digital mammography versus 3D digital breast tomosynthesis in a large community-based practice”.

[46] S. Zackrisson *et al.*, “One-view breast tomosynthesis versus two-view mammography in the Malmö Breast Tomosynthesis Screening Trial (MBTST): a prospective, population-based, diagnostic accuracy study,” *Lancet Oncol*, vol. 19, no. 11, pp. 1493–1503, 2018, doi: https://doi.org/10.1016/S1470-2045(18)30521-7.

[47] M. Noroozian *et al.*, “Digital Breast Tomosynthesis Is Comparable to Mammographic Spot Views for Mass Characterization,” *Radiology*, vol. 262, no. 1, pp. 61–68, Jan. 2012, doi: 10.1148/radiol.11101763.

[48] K. R. Brandt *et al.*, “Can Digital Breast Tomosynthesis Replace Conventional Diagnostic Mammography Views for Screening Recalls Without Calcifications? A Comparison Study in a Simulated Clinical Setting,” *American Journal of Roentgenology*, vol. 200, no. 2, pp. 291–298, Feb. 2013, doi: 10.2214/AJR.12.8881.

[49] C. M. Hakim, D. M. Chough, M. A. Ganott, J. H. Sumkin, M. L. Zuley, and D. Gur, “Digital Breast Tomosynthesis in the Diagnostic Environment: A Subjective Side-by-Side Review,” *American Journal of Roentgenology*, vol. 195, no. 2, pp. W172–W176, Aug. 2010, doi: 10.2214/AJR.09.3244.

[50] M. L. Zuley *et al.*, “Digital Breast Tomosynthesis versus Supplemental Diagnostic Mammographic Views for Evaluation of Noncalcified Breast Lesions,” *Radiology*, vol. 266, no. 1, pp. 89–95, Jan. 2013, doi: 10.1148/radiol.12120552.

[51] T. I. Alshafeiy, J. V. Nguyen, C. M. Rochman, B. T. Nicholson, J. T. Patrie, and J. A. Harvey, “Outcome of Architectural Distortion Detected Only at Breast Tomosynthesis versus 2D Mammography,” *Radiology*, vol. 288, no. 1, pp. 38–46, Jul. 2018, doi: 10.1148/radiol.2018171159.

[52] A. Vourtsis, “Three-dimensional automated breast ultrasound: Technical aspects and first results,” *Diagn Interv Imaging*, vol. 100, no. 10, pp. 579–592, Oct. 2019, doi: 10.1016/j.diii.2019.03.012